Why early CAR-T conversations matter in multiple myeloma (Sponsored)

This podcast episode is sponsored by Johnson & Johnson and Legend Biotech. Dr. Paresh Patel and multiple myeloma patient Julia P. have been compensated by Johnson & Johnson and Legend Biotech for their time to participate in this podcast. In this episode of Podnosis: The Pulse of the Healthcare Industry, listeners hear a candid conversation about multiple myeloma from the patient and physician perspectives. A patient who underwent CAR-T therapy and her community oncologist, Dr. Paresh Patel, share how early education, trust and collaboration shaped her treatment journey. The patient walks through her experience from diagnosis to CAR-T, describing how informed decision-making and self-advocacy helped her navigate an evolving treatment landscape. She reflects on the emotional and practical challenges of multiple myeloma therapies, the importance of caregiver support and what the possibility of a treatment-free interval meant to her. Dr. Patel discusses the role of community oncologists in managing complex diseases like multiple myeloma, emphasizing why CAR-T should remain part of the treatment conversation early on. He explores timing, referral considerations and the value of clear communication as patients move between local care and specialized centers. At its core, this episode is about partnership and what is possible when patients and care teams navigate complexity together.See omnystudio.com/listener for privacy information.